Bruker Co. (NASDAQ:BRKR - Free Report) - Investment analysts at Zacks Research lowered their Q1 2025 earnings estimates for shares of Bruker in a research report issued on Thursday, March 6th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $0.44 for the quarter, down from their previous estimate of $0.52. The consensus estimate for Bruker's current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker's Q3 2025 earnings at $0.70 EPS, FY2025 earnings at $2.67 EPS, Q2 2026 earnings at $0.70 EPS, Q3 2026 earnings at $0.82 EPS, FY2026 earnings at $3.11 EPS and FY2027 earnings at $3.60 EPS.
Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%.
Other analysts also recently issued research reports about the stock. UBS Group started coverage on shares of Bruker in a report on Tuesday, December 10th. They set a "neutral" rating and a $66.00 target price for the company. Guggenheim restated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Stifel Nicolaus lowered their target price on Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a research note on Friday, February 14th. The Goldman Sachs Group raised Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price target for the company in a report on Thursday, December 5th. Finally, Barclays decreased their price objective on Bruker from $69.00 to $65.00 and set an "overweight" rating on the stock in a report on Monday, February 10th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $70.50.
Read Our Latest Analysis on BRKR
Bruker Stock Performance
BRKR stock traded down $1.84 during midday trading on Friday, reaching $45.56. 2,530,365 shares of the company were exchanged, compared to its average volume of 1,262,785. Bruker has a one year low of $44.94 and a one year high of $94.86. The firm has a market capitalization of $6.91 billion, a price-to-earnings ratio of 59.95, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The business has a 50-day moving average price of $54.97 and a two-hundred day moving average price of $59.00. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77.
Hedge Funds Weigh In On Bruker
Institutional investors have recently modified their holdings of the business. New York State Teachers Retirement System increased its position in Bruker by 2.4% during the 3rd quarter. New York State Teachers Retirement System now owns 38,447 shares of the medical research company's stock worth $2,655,000 after purchasing an additional 900 shares in the last quarter. US Bancorp DE grew its position in Bruker by 2.1% during the 3rd quarter. US Bancorp DE now owns 12,700 shares of the medical research company's stock worth $877,000 after acquiring an additional 260 shares during the last quarter. Van ECK Associates Corp increased its holdings in Bruker by 16.2% in the 3rd quarter. Van ECK Associates Corp now owns 56,451 shares of the medical research company's stock worth $3,899,000 after purchasing an additional 7,881 shares in the last quarter. Amalgamated Bank increased its stake in shares of Bruker by 5.8% in the third quarter. Amalgamated Bank now owns 53,356 shares of the medical research company's stock valued at $3,685,000 after buying an additional 2,924 shares during the period. Finally, Forte Capital LLC ADV raised its holdings in Bruker by 28.2% in the 3rd quarter. Forte Capital LLC ADV now owns 9,100 shares of the medical research company's stock valued at $628,000 after buying an additional 2,000 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.
Bruker Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Monday, March 17th will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.44%. The ex-dividend date is Monday, March 17th. Bruker's payout ratio is presently 26.32%.
About Bruker
(
Get Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Further Reading
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
